{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04017819",
            "orgStudyIdInfo": {
                "id": "IRB-49038"
            },
            "secondaryIdInfos": [
                {
                    "id": "LUN0108",
                    "type": "OTHER",
                    "domain": "OnCore"
                },
                {
                    "id": "IRB-49038",
                    "type": "OTHER",
                    "domain": "Stanford IRB"
                }
            ],
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "Biodistribution&Pharmacokinetic of Position Emission Tomography(PET) Radiopharmaceutical 18F C SNAT4",
            "officialTitle": "Biodistribution and Pharmacokinetic Study of the Positron Emission Tomography (PET) Radiopharmaceutical [18F]-C-SNAT4",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "biodistribution-pharmacokinetic-of-position-emission-tomography-pet-radiopharmaceutical-c"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-07-02",
            "studyFirstSubmitQcDate": "2019-07-10",
            "studyFirstPostDateStruct": {
                "date": "2019-07-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Stanford University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institutes of Health (NIH)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Primary Objectives\n\n* Determine the biodistribution of \\[18F\\]-C-SNAT4 in 5 healthy volunteers. Secondary Objectives\n* Determine the dosimetry of \\[18F\\]-C-SNAT4 PET in healthy volunteers and patients with lung cancer.\n* Determine the acute toxicity of \\[18F\\]-C-SNAT4 PET in healthy volunteers and patients with lung cancer.\n* Determine whether uptake in \\[18F\\]-C-SNAT4 PET imaging is significantly different in tumor and corresponding contralateral noncancer tissue in patients with lung cancer (tested by Wilcoxon test) before the therapy.\n* Determine/verify the safety profile of the \\[18F\\]-C-SNAT4 radiotracer, as an imaging agent in patients with lung cancer.\n* Determine the time of maximal \\[18F\\]-C-SNAT4 radiotracer uptake post injection."
        },
        "conditionsModule": {
            "conditions": [
                "Cancer",
                "Lung Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Healthy volunteers (Group 1)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Group 1(n = 5) healthy volunteers. Each participant in this part of the study will receive a single dose of \\[18F\\]-C-SNAT4 and then undergo three times of whole body (WB) PET/CT scans (Scan 1: 60 minutes dynamic scan; Scan 2: WB skull base-thigh at 90 minutes +/- 10 minutes post injection; Scan 3: WB skull base-thigh at 120 minutes +/- 10 minutes post-injection of \\[18F\\]-C-SNAT4).",
                    "interventionNames": [
                        "Drug: 18F-C-SNAT4",
                        "Procedure: Positron emission tomography (PET)/Computed tomography (CT) Scan"
                    ]
                },
                {
                    "label": "Patients with newly diagnosed lung cancer (Group 2)",
                    "type": "EXPERIMENTAL",
                    "description": "Group2 (n = 5) newly diagnosed lung cancer. Each participant in this part of the study will receive a single dose of \\[18F\\]-C-SNAT4 and then undergo three times of whole body (WB) PET/CT scans (Scan 1: 60 minutes dynamic scan; Scan 2: WB skull base-thigh at 90 minutes +/- 10 minutes post injection; Scan 3: WB skull base-thigh at 120 minutes +/- 10 minutes post-injection of \\[18F\\]-C-SNAT4).",
                    "interventionNames": [
                        "Drug: 18F-C-SNAT4",
                        "Procedure: Positron emission tomography (PET)/Computed tomography (CT) Scan"
                    ]
                },
                {
                    "label": "Patients with lung cancer undergoing non-surgical tx (Group 3)",
                    "type": "EXPERIMENTAL",
                    "description": "Group 3 (n = 10) lung cancer after non-surgical therapy. Each participant in this part of the study will receive a total of 2 doses of \\[18F\\]-C-SNAT4 (on 2 separate occasions spaced at least 1 week apart, each of which will be followed by undergoing a \\[18F\\]-C-SNAT4 PET/CT scan)",
                    "interventionNames": [
                        "Drug: 18F-C-SNAT4",
                        "Procedure: Positron emission tomography (PET)/Computed tomography (CT) Scan"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "18F-C-SNAT4",
                    "description": "Radiotracer- Dose 10 mCi",
                    "armGroupLabels": [
                        "Healthy volunteers (Group 1)",
                        "Patients with lung cancer undergoing non-surgical tx (Group 3)",
                        "Patients with newly diagnosed lung cancer (Group 2)"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Positron emission tomography (PET)/Computed tomography (CT) Scan",
                    "description": "Positron emission tomography (PET)/Computed tomography (CT) Scan",
                    "armGroupLabels": [
                        "Healthy volunteers (Group 1)",
                        "Patients with lung cancer undergoing non-surgical tx (Group 3)",
                        "Patients with newly diagnosed lung cancer (Group 2)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Biodistribution of [18F]-C-SNAT4",
                    "description": "Whole-body \\[18F\\]-C-SNAT4 PET scans will be performed at 60 min post intravenous injection of the PET tracer in Group 1 of 5 healthy volunteers",
                    "timeFrame": "1 day"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Dosimetry of [18F]-C-SNAT4",
                    "description": "Radiation dosimetry of the \\[18F\\]-C-SNAT4 radiotracer will be measured through careful monitoring of each participant's vital signs in Group 1 and group 2. Time-Activity curves will be graphed by measuring activity in various organs using multiple PET/CT scans (1 hour dynamic scan, 1 hour and 2 hours) after tracer injection. Absorbed radiation will be calculated.",
                    "timeFrame": "1 day"
                },
                {
                    "measure": "Toxicity of [18F]-C-SNAT4",
                    "description": "The acute \\[18F\\]-C-SNAT4 toxicity will be assessed as related adverse events, including laboratory abnormalities, that occur within 7 days of the infusion of \\[18F\\]-C-SNAT4.",
                    "timeFrame": "7 days"
                },
                {
                    "measure": "18F]-C-SNAT4 Uptake",
                    "description": "The tumor uptake of \\[18F\\]-C-SNAT4 PET will be compared with the corresponding contralateral non-cancer tissue in patients with lung cancer before the therapy in Group 2 and 3. SUVmax measurements will be taken from the pre-treatment scan.",
                    "timeFrame": "1 day"
                },
                {
                    "measure": "The Maximal [18F]-C-SNAT4 Uptake as PET Radiotracer",
                    "description": "The time of maximal \\[18F\\]-C-SNAT4 radiotracer uptake post-injection will be assessed in Group 2 and 3. Time-Activity Curves (TAC) will be graphed by measuring activity in tumor after tracer injection. The maximal of \\[18F\\]-C-SNAT4 radiotracer uptake post-injection in lung cancer patients will be determined from these time activity curves.",
                    "timeFrame": "1 day"
                },
                {
                    "measure": "[18F]-C-SNAT4 PET Imaging Signal in Responders and Non-responders",
                    "description": "The \\[18F\\]-C-SNAT4 PET scan signal from pre-therapy to one week after initiation of therapy in Group 3 will be compared both in treatment responders vs. non-responders. SUVmax will be measured in both the pre-treatment and one-week post-initiation of treatment scans.",
                    "timeFrame": "7 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* ANC \u2265 1.5 x 109/L without myeloid growth factor support for 7 days preceding lab assessment\n* Hgb \u2265 9 g/dL (90 g/L); \\< 9 g/dL (\\< 90 g/L) is acceptable if Hgb corrected to \u2265 9 g/dL (90 g/L) as by growth factor or transfusion prior to PET scan\n* Platelet count \u2265 100 x 109/L w/o blood transfusions for 7 days preceding lab assessment\n* Bilirubin \u2264 1.5 x upper limit of normal (ULN) except for pts with documented history of Gilbert's disease\n* ALT \u2264 2.5 x ULN\n* AST \u2264 2.5 x ULN\n* Alkaline phosphatase (AP) \u2264 3 x ULN\n* If a women of childbearing potential (WCBP): negative early pregnancy test (EPT)\n* Karnofsky Performance Status (KPS) \u2265 60\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Has already begun non-surgical therapy for any recurrence, prior to the first \\[18F\\]-C-SNAT4 PET/CT scan\n* Severe/uncontrolled inter-current illness within the previous 28 days prior to PET scan.\n* Any other significant co-morbid conditions that in the opinion of the Investigator would impair study participation or cooperation.\n* History of allergic reactions to IV contrasts or reactions attributed to compounds of similar chemical or biological composition to \\[18F\\]-C-SNAT4 used in study.\n* Pregnant or nursing\n* Patients who exceed the safe weight limit of the PET/CT bed (204.5 kg) or who cannot fit through the PET/CT bore (diameter 70 cm).",
            "healthyVolunteers": true,
            "sex": "ALL",
            "genderBased": true,
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "David Marcellus",
                    "role": "CONTACT",
                    "phone": "650-723-4547",
                    "email": "dmarcel2@stanford.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Andrei H Iagaru, MD",
                    "affiliation": "Stanford University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford University",
                    "status": "RECRUITING",
                    "city": "Stanford",
                    "state": "California",
                    "zip": "94304",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "David Marcellus",
                            "role": "CONTACT",
                            "phone": "650-723-4547",
                            "email": "dmarcel2@stanford.edu"
                        },
                        {
                            "name": "Andrei Iagaru, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.42411,
                        "lon": -122.16608
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M21258",
                    "name": "Radiopharmaceuticals",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}